MS und Kinderwunsch

Links und Quellen

• St. Josef-Hospital - Katholisches Klinikum Bochum
• Klinik für Neurologie
• Praxis für Pränatalmedizin
• Migräne und Kinderwunsch

Unter diesen Internetadressen finden Sie weitere nützliche Hinweise zum Thema Multiple Sklerose:

• Deutsche Multiple Sklerose Gesellschaft
• Aktion Multiple Sklerose Erkrankter, Landesverband der DMSG in Baden-Württemberg - AMSEL e.V.
• Kompetenznetz Multiple Sklerose
• DMSG - Plan Baby
• Impfen bei Immunerkrankungen
• MS Perspektive
• Interview/Podcast mit Nele Handwerker (MS Perspektive)
• Impfprojekt VAC-MAC
  Arztbrief „Impfen bei Immunerkrankungen“ (pdf-Download)

 

• Eigene Publikationen
  1. Cladribine and pregnancy in women with multiple sclerosis: The first cohort study. Dost-Kovalsky K, Thiel S, Ciplea AI, Gold R, Hellwig K. Mult Scler. 2023 Mar;29(3):461-465.
  2. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study. Ciplea AI, Kurzeja A, Thiel S, Haben S, Alexander J, Adamus E, Hellwig K. Mult Scler. 2022 Sep;28(10):1641-1650.
  3. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. Hellwig K, Tokic M, Thiel S, Esters N, Spicher C, Timmesfeld N, Ciplea AI, Gold R, Langer-Gould A. JAMA Netw Open. 2022 Jan 4;5(1): e2144750.
  4. The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results. Thiel S, Ciplea AI, Gold R, Hellwig K. Ther Adv Neurol Disord. 2021 Nov 22;14:17562864211054956.
  5. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. Kümpfel T*, Thiel S*, Meinl I, Ciplea AI, Bayas A, Hoffmann F, Hofstadt-van Oy U, Hoshi M, Kluge J, Ringelstein M, Aktas O, Stoppe M, Walter A, Weber M, Ayzenberg I, Hellwig K. 2020 Dec 17;8(1):e913. * contributed equaly
  6. Dimethyl fumarate transfer into human milk. Ciplea AI, Datta P, Rewers-Felkins K, Baker T, Gold R, Hale TW, Hellwig K. Ther Adv Neurol Disord. 2020 Oct 31;13:1756286420968414.
  7. Exposure to natalizumab during pregnancy and lactation is safe – Commentary. Ciplea AI, Hellwig K. Mult Scler. 2020 Jul;26(8):892-893.
  8. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes. Ciplea AI, Langer-Gould A, Stahl A, Thiel S, Queisser-Wahrendorf A, Gold R, Hellwig K. Neurol Neuroimmunol Neuroinflamm. 2020 May 20;7(4):e757.
  9. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M, Gold R, Hellwig K. Neurol Neuroimmunol Neuroinflamm. 2020 Apr 23;7(4):e723.
  10. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K. Mult Scler. 2016 May;22(6):801-9.
  11. Glatiramer acetate during early pregnancy: A prospective cohort study. Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A, Gold R, Hellwig K. Mult Scler. 2016 May;22(6):810-6.
  12. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. Hellwig K, Chen LH, Stancyzk FZ, Langer-Gould AM. PLoS One. 2016 Mar 7;11(3):e0149094.
  13. Multiple sclerosis and family planning. Hellwig K. Neurodegener Dis Manag. 2015;5(6 Suppl):39-42.
  14. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A, Elias-Hamp B, Menck S, Gold R, Langer-Gould A. JAMA Neurol. 2015 Oct;72(10):1132-8.
  15. Pregnancy in multiple sclerosis. Hellwig K. Eur Neurol. 2014;72 Suppl 1:39-42.
  16. Artificial reproductive techniques in multiple sclerosis. Hellwig K, Correale J. Clin Immunol. 2013 Nov;149(2):219-24.
  17. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Hellwig K, Haghikia A, Rockhoff M, Gold R. Ther Adv Neurol Disord. 2012 Sep;5(5):247-53.
  18. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Hellwig K, Kleiter I, Gold R. Neurology. 2012 Jan 31;78(5):371; author reply 371.
  19. Progressive multifocal leukoencephalopathy and natalizumab. Hellwig K, Gold R. J Neurol. 2011 Nov;258(11):1920-8.
  20. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Bayas A, Penzien J, Hellwig K. Acta Neurol Scand. 2011 Oct;124(4):290-2.
  21. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Hellwig K, Haghikia A, Gold R. Mult Scler. 2011 Aug;17(8):958-63.
  22. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. J Neurol Sci. 2011 Aug 15;307(1-2):164-5.
  23. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Hellwig K, Gold R. Neurology. 2011 Apr 12;76(15):1362-3; author reply 1363.
  24. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. Hellwig K, Gold R. J Neurol. 2011 Mar;258(3):502-3.
  25. Parenthood and immunomodulation in patients with multiple sclerosis. Hellwig K, Haghikia A, Gold R. J Neurol. 2010 Apr;257(4):580-3.
  26. Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis. Hellwig K, Haghikia A, Agne H, Beste C, Gold R. Arch Neurol. 2009 Dec;66(12):1580-1.
  27. Interferon beta, birth weight and pregnancy in multiple sclerosis. Hellwig K, Agne H, Gold R. J Neurol. 2009 May;256(5):830-1.
  28. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Hellwig K, Beste C, Schimrigk S, Chan A. Ther Adv Neurol Disord. 2009 Jan;2(1):7-11.
  29. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Eur Neurol. 2009;61(2):65-8.
  30. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S, Schwödiauer V, Gold R. Acta Neurol Scand. 2008 Jul;118(1):24-8.
  31. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T, Chan A, Gold R. Arch Neurol. 2008 May;65(5):656-8.
  32. Increased MS relapse rate during assisted reproduction technique. Hellwig K, Beste C, Brune N, Haghikia A, Müller T, Schimrigk S, Gold R. J Neurol. 2008 Apr;255(4):592-3.
  33. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N, Przuntek H, Müller T. Clin Neuropharmacol. 2006 Sep-Oct;29(5):286-91.
  34. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. Hellwig K, Lukas C, Brune N, Schimrigk S, Przuntek H, Müller T. ScientificWorldJournal. 2006 Apr 6;6:460-5.
  35. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. Hellwig K, Stein FJ, Przuntek H, Müller T. BMC Neurol. 2004 Nov 7;4(1):18.
• Zitierte Literatur
  1. Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T. et al. Mitoxantrone and etoposide in breast milk. Am J Hematol. 1995;48:131-2.
  2. Bayas A, Penzien J, Hellwig K. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand. 2011;124(4):290-2.
  3. Ciplea AI, Hellwig K. Exposure to natalizumab during pregnancy and lactation is safe – Commentary. Mult Scler. 2020;26(8):892-893.
  4. Ciplea AI, Datta P, Rewers-Felkins K, Baker T, Gold R. et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord. 2020;13:1756286420968414.
  5. Ciplea AI, Kurzeja A, Thiel S, Haben S, Alexander J et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study. Mult Scler. 2022;28(10):1641-1650.
  6. Ciplea AI, Langer-Gould A, de Vries A, Schaap T, Thiel S, Ringelstein M. et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723.
  7. Ciplea AI, Langer-Gould A, Stahl A, Thiel S, Queisser-Wahrendorf A. et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e757.
  8. Cocco E, Sardu C, Gallo P. et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler. 2008;14:1225-33.
  9. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. The New England journal of medicine. 1998;339:285-91.
  10. Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005;65:1961-3.
  11. de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T. et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. 2004;10:596-7.
  12. D'Hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010;81:38-41.
  13. Dost-Kovalsky K, Thiel S, Ciplea AI, Gold R, Hellwig K. Cladribine and pregnancy in women with multiple sclerosis: The first cohort study. Mult Scler. 2023;29(3):461-465.
  14. Ferrero S, Pretta S, Ragni N. Multiple sclerosis: management issues during pregnancy. European journal of obstetrics, gynecology, and reproductive biology. 2004;115:3-9.
  15. Greenberger PA, Odeh YK, Frederiksen MC, Atkinson AJ, Jr. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther. 1993;53:324-8.
  16. Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:900-8.
  17. Hellwig, K. Pregnancy in multiple sclerosis. Eur Neurol. 2014;72 Suppl 1:39-42.
  18. Hellwig, K. Multiple sclerosis and family planning. Neurodegener Dis Manag. 2015;5(6 Suppl):39-42.
  19. Hellwig K, Agne H, Gold R. Interferon beta, birth weight and pregnancy in multiple sclerosis. J Neurol. 2009;256(5):830-1.
  20. Hellwig K, Beste C, Brune N, Haghikia A, Müller T. et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008;255(4):592-3.
  21. Hellwig K, Beste C, Schimrigk S, Chan A. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2(1):7-11.
  22. Hellwig K, Brune N, Haghikia A, Müller T, Schimrigk S. et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand. 2008;118(1):24-8.
  23. Hellwig K, Chen LH, Stancyzk FZ, Langer-Gould AM. Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility. 2016;11(3):e0149094.
  24. Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol. 2013;149(2):219-24.
  25. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol. 2011;258(11):1920-8.
  26. Hellwig K, Gold R. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology. 2011;76(15):1362-3.
  27. Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258(3):502-3.
  28. Hellwig K, Haghikia A, Agne H, Beste C, Gold R. Protective effect of breastfeeding in postpartum relapse rate of mothers with multiple sclerosis. Arch Neurol. 2009;66(12):1580-1.
  29. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257(4):580-3.
  30. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958-63.
  31. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247-53.
  32. Hellwig K, Kleiter I, Gold R. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2012;78(5):371.
  33. Hellwig K, Lukas C, Brune N, Schimrigk S, Przuntek H. et al. Repeat intrathecal triamcinolone acetonide application reduces acute occurring painful dysesthesia in patients with relapsing remitting multiple sclerosis. ScientificWorldJournal. 2006;6:460-5.
  34. Hellwig K, Rockhoff M, Herbstritt S, Borisow N, Haghikia A. et al. Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol. 2015;72(10):1132-8.
  35. Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis.Eur Neurol. 2009;61(2):65-8.
  36. Hellwig K, Schimrigk S, Chan A, Epplen J, Gold R. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci. 2011;307(1-2):164-5.
  37. Hellwig K, Schimrigk S, Fischer M, Haghikia A, Müller T. et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008;65(5):656-8.
  38. Hellwig K, Schimrigk S, Lukas C, Hoffmann V, Brune N. et al. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Clin Neuropharmacol. 2006;29(5):286-91.
  39. Hellwig K, Stein FJ, Przuntek H, Müller T. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol. 2004;4(1):18.
  40. Hellwig K, Tokic M, Thiel S, Esters N, Spicher C. et al. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy. JAMA Netw Open. 2022;5(1): e2144750.
  41. Herbstritt S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016;22(6):810-6.
  42. Hoffmann LA, Kumpfel T, Heer I, Hohlfeld R. Pregnancy and immunomodulatory therapy in multiple sclerosis patients. Nervenarzt. 2006;77:663-4, 6-8, 70.
  43. Kümpfel T, Thiel S, Meinl I, Ciplea AI, Bayas A. et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany. 17;8(1):e913.
  44. Langer-Gould A, Huang SM, Gupta R. et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66:958-63.
  45. Laplaud DA, Leray E, Barriere P, Wiertlewski S, Moreau T. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology. 2006;66:1280-1.
  46. Lu E, Wang BW, Guimond C. et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology. 2012; 79: 1130 – 1135
  47. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68:186-91.
  48. O'Connor PW, Goodman A, Kappos L. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858-65.
  49. Park-Wyllie L, Mazzotta P, Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385-92.
  50. Thiel S, Ciplea AI, Gold R, Hellwig K. The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results. Ther Adv Neurol Disord. 2021;14:17562864211054956.
  51. Thiel S, Langer-Gould A, Rockhoff M, Haghikia A, Queisser-Wahrendorf A. et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis-A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler. 2016;22(6):801-9.